Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
Portfolio Pulse from Vandana Singh
Tango Therapeutics Inc. (NASDAQ:TNGX) has decided to discontinue its TNG348 program due to liver toxicity observed in patients. The company will now focus on its PRMT5 program and expects to provide updates on TNG908 and TNG462 later this year. Despite the setback, Tango's cash runway extends into 2027.
May 23, 2024 | 4:53 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tango Therapeutics has discontinued its TNG348 program due to liver toxicity in patients. The company will now focus on its PRMT5 program and expects to provide updates on TNG908 and TNG462 later this year. Despite the setback, Tango's cash runway extends into 2027.
The discontinuation of the TNG348 program due to liver toxicity is a significant setback for Tango Therapeutics. However, the company's focus on its PRMT5 program and the extended cash runway into 2027 provide some reassurance. The immediate impact on the stock price is likely negative due to the halted program.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
AstraZeneca's Lynparza (olaparib) was part of the TNG348 study in combination with Tango Therapeutics' TNG348. The discontinuation of TNG348 may have a minor impact on AstraZeneca, but no patients had yet received the combination treatment.
AstraZeneca's Lynparza was part of the TNG348 study, but since no patients had yet received the combination treatment, the impact on AstraZeneca is expected to be minor.
CONFIDENCE 80
IMPORTANCE 30
RELEVANCE 30